Respiratory

Synergy Pharma Products

NEW LAUNCH

Tulobuterol Patch

Tulobuterol Patch is a long-acting transdermal bronchodilator designed for the management of obstructive airway diseases, including bronchial asthma, chronic and acute bronchitis, and emphysema. Administered once daily, the patch ensures 24-hour sustained release, offering effective symptom control—especially during night-time and early morning hours. Suitable for patients from 6 months of age and up, it is an ideal solution for those who have difficulty with oral or inhaled medications. With proven bioequivalence, excellent skin permeability, and a favorable safety profile, Tulobuterol Patch represents a reliable and patient-friendly treatment option in respiratory care.

Download a presentation

Respiratory

Products available only from and to countries where there is no valid patent protection and according to the applicable law

Budesonide

Strength

1mg/2ml – 0.5mg/2ml – 0.25mg/2ml

200 mcg/actuation

Fluticasone

Strength

50 mcg/actuation

Mometasone

Strength

50 mcg/actuation

Salbutamol + Ipratropium

Strength

2.5mg + 0.5mg/2.5ml

Salmeterol + Fluticasone

Strength

25mcg + 125mcg
25mcg + 250mcg
50mcg + 250mcg
50mcg + 500mcg

Active Ingredient Under Development

Fluticasone

Strength

0.5mg/2ml – 2mg/2ml

Tiotropium

Strength

18 mcg/capsule

XTONIC

An innovave Medical Device, patented, with European certification from Cermet.

Xtonic®, a combination of sodium chloride and D-mannitol, in an optimal ratio, has been specifically designed for the inhalator treatment of Cystic Fibrosis, Primary ciliary dyskinesia and Bronchiectasis.

The combination of two effective ingredients in an optimal dosage to achieve a better tolerability and efficacy compared to hypertonic saline or mannitol, alone

OUR PRODUCTS

In addition to its focus on finished dosage forms, Synergy Swiss Pharma has also made significant expansions into various sectors. The company has established expertise in the fields of respiratory, cardiovascular, psychiatry, gastroenterology, and ophthalmology. Its portfolio includes a wide range of injectable products, encompassing both slow and fast-release formulations, with innovative applications for improved patient care.

Furthermore, Synergy Swiss Pharma has expanded its focus beyond pharmaceuticals and ventured into the realms of Medical Devices and Food Supplements. This diversification allows the company to provide a comprehensive range of healthcare solutions, catering to different aspects of patient well-being.